Startups
Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 5, 2025 | Braveheart Bio Raises $185M in Series A Funding | Braveheart Bio, a San Francisco, CA-based clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, raised $185M in Series A financing. Backers included Andreessen Horow... |
| Braveheart Bio | “Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.” |
Reviews 0
FAQ about Braveheart Bio
What has the press written about Braveheart Bio?
Parsers VC has collected 3 articles mentioning Braveheart Bio, among them “Braveheart Bio Raises $185M in Series A Funding” (Nov 5, 2025) and “Braveheart Bio”.
Is Braveheart Bio still active?
Yes, Braveheart Bio is active; its latest activity on Parsers VC dates from Nov 5, 2025.